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Background: Coronary artery disease (CAD) is the major leading cause of death worldwide. The national practice
guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) promote the use
of several medical therapies for secondary prevention for patients with CAD. The purpose of this study was to
evaluate whether ACS patients, admitted into two tertiary referral medical centers in Beirut, Lebanon, are
discharged on optimal medical therapy based on the current AHA/ACC guidelines.
Methods: We reviewed the medical records of all patients with ACS who were admitted to the coronary care units
(CCU) of two hospitals in Beirut, Lebanon between May and August 2012. Discharge prescriptions were reviewed
and rating for the appropriateness of discharge cardiac medications was based on the AHA/ACC guidelines. We
assessed whether patients were discharged on antiplatelet therapy, β-blockers, angiotensin converting enzymes
inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), statins, and nitrates, unless contraindicated or not
tolerated. In addition, we assessed whether patients and/or their caregivers were counseled about their disease(s)
and discharge medications.
Results: 186 patients with a mean age of 63 ± 11.78 years, 70.4% of which were males, were admitted with ACS and
were included in the study. Fifty three (28.5%) patients had ST elevation MI (STEMI), 64 (34.4%) had non-ST-elevation
myocardial infarction (NSTEMI) and 69 (37.1%) had unstable angina (USA). Sixty two patients (33.3%) were treated with
medical therapy and 124 patients (66.7%) underwent percutaneous coronary intervention (PCI).
Among eligible patients, 98.9% were discharged on aspirin, 89.1% on dual antiplatelet therapy (aspirin + thienopyridine
or ticagrelor), 90.5% on a β-blocker, 81.9% on an ACEI or ARB, 89.8% on a statin, and 19.4% on nitroglycerin. Overall,
62.9% of the patients received the optimal cardiovascular drug therapy (the combination of dual antiplatelet therapy, a
β-blocker, an ACEIs or an ARB, and a statin), 55.1% were counseled on their disease state(s) and drug therapy, and
92.2% and 55.9% were counseled on smoking cessation and life style changes, respectively.
Conclusion: In patients admitted with ACS, discharge cardiac medications are prescribed at suboptimal rates.
Education of healthcare providers and implementation of ACS discharge protocols may help improve compliance with
ACC/AHA guidelines. In addition, clinicians should be encouraged to provide adequate patient counseling.
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Coronary artery disease (CAD) is the major leading
cause of death worldwide (WHO 2011). According to
the World Health Organization, around 17 million
people die of coronary diseases each year and over 80%
of CAD deaths take place in low and middle-income
countries (WHO 2011). Unstable angina (USA), non-
ST-elevation myocardial infarction (NSTEMI), and
ST-segment elevation myocardial infarction (STEMI)
are common manifestations of acute coronary disease and
are major causes of hospitalizations (Yang et al. 2006;
Setoguchi et al. 2008; Smith et al. 2006). Conversely, the
rate has been decreasing during the last 3 decades as a re-
sult of better coronary risk factor reduction and better cli-
nical management (Setoguchi et al. 2008; Smith et al. 2006).
The national practice guidelines from the American
College of Cardiology (ACC) and American Heart Associ-
ation (AHA) promote the use of several medical therapies
to reduce recurrence of ischemic events and moratlity
(Smith et al. 2006; Kushner et al. 2009; Anderson et al.
2013). These medications include dual antiplatelet agents,
β-blockers, angiotensin converting enzymes inhibitors
(ACEIs) or angiotensin receptor blockers (ARBs), statins,
and nitroglycerin (Kushner et al. 2009; Anderson et al.
2013). Death may be prevented during the post-infarction
period by different mechanisms in the body; reduction of
myocardial ischemia and re-infarction and/or left ven-
tricular dysfunction (LVD) and inhibition of platelet aggre-
gation and rupture (Kushner et al. 2009; Anderson et al.
2013; Frishman and Cheng 1999). To note, β-blockers are
beneficial by attenuating the arrhythmogenic potential of
damaged myocardium and by reducing myocardial oxygen
requirements and thereby the occurrence of ischemia
(Frishman and Cheng 1999). While patients recovering
from UA/NSTEMI with heart failure, LV dysfunction,
hypertension, or diabetes mellitus, should receive an ACEI
or an ARB if the former is not tolerated (Class A, Level of
evidence: A), the use of these agents is reasonable in the
absence of LV dysfunction, hypertension, or diabetes mel-
litus (Class IIa, Level of Evidence: A) (Anderson et al.
2013). On the other hand, all patients with STEMI should
be prescribed at discharge an ACEI (or an ARB for patients
who do not tolerate an ACEI) (Kushner et al. 2009). ACEIs
and ARBs inhibit the renin -angiotensin system and prevent
ventricular remodeling, slow the thickening of the coronary
vascular wall, improve subendocardial perfusion as a conse-
quence of lowering left ventricular diastolic pressure, or
modulating hormonal factors that influence coronary tone
or myocardial perfusion (Kushner et al. 2009; Anderson
et al. 2013; Frishman and Cheng 1999). Statins play a role
in ACS by involving multiple anti-inflammatory activities to
decrease the extent of myocardial necrosis and preserve
myocardial viability, ultimately resulting in increased ven-
tricular function (Yamanaka et al. 2012). Yamanaka et al.showed in the Korean Acute Myocardial Infarction Registry
(KAMIR) trial that patients with low LDL <100 mg/dl
would benefit from statins in reducing the risk of 1-year all-
cause death and 1-year major adverse cardiac events
(Yamanaka et al. 2012). Antithrombotic therapy is es-
sential to modify the disease process and its progression
to death, or recurrent myocardial infarction (MI) (Kushner
et al. 2009; Anderson et al. 2013). The use of a combi-
nation of dual antiplatelet therapy, β- blockers, ACEIs/
ARBs and of statins is essential to all ACS patients with no
contraindications to these medications. Nitroglycerin is
prescribed at discharge to treat ischemic symptoms and is
administered only when needed (Kushner et al. 2009;
Anderson et al. 2013).
Despite the general consensus on the efficacy of these
drugs for secondary prevention of CAD, adherence to
these guidelines is highly variable among physicians (Eagle
et al. 2004; Margulis et al. 2011; Lee et al. 2010; Spencer
et al. 2001). Previous studies showed that these therapies
are neither consistently prescribed when appropriate nor
adhered to by patients in the long term (Setoguchi et al.
2008; Eagle et al. 2004; Lappe et al. 2004). In addition,
existing research suggest that both filling prescriptions
and adherence to cardiac medications are improved by
complete hospital discharge recommendations especially if
physicians highly encourage their patients to get their
medications and provide drug counseling (Eagle et al.
2004; Lappe et al. 2004). Limited studies are available in
Lebanon, a third world country, regarding the proper dis-
charge medications and patient education for ACS pa-
tients. In our study, we evaluated whether ACS patients
were discharged on appropriate cardiac medications (anti-
platelets, β-blockers, ACEIs or ARBs, statins, and short-
acting nitrates) based on ACC/ AHA guideline (Kushner
et al. 2009; Anderson et al. 2013) in 2 major Lebanese hos-
pitals. In addition, we assessed whether patients received
education on their disease state, medications, and lifestyle
modifications.
Methodology
This is an observational study that included all ACS pa-
tients discharged from the coronary care unit (CCU) from
May till August 2012 from two teaching tertiary referral
medical centers in Beirut- Lebanon. Data was collected via
a review of inpatient medical records and included patient
demographics, co-morbidities, in-hospital management,
vital signs, laboratory findings, smoking status, and dis-
charge prescriptions. Upon discharge, patients were asked
whether they received education about their current dis-
ease state, life style modification, and discharge medica-
tions. The primary endpoint was to evaluate the use of
ACC/AHA guideline recommended cardiac medications
(Kushner et al. 2009; Anderson et al. 2013) at hospital dis-
charge in patients admitted for ACS. For the purpose of
Table 1 Baseline characteristics (n = 186)
Demographics










History of cardiac disease (%)
Hypertension 93.0
Atrial fibrillation 5.9
Congestive heart failure 14.0
Known CAD 65.6














CABG: coronary artery bypass graft; GI: gastrointestinal; DVT: deep
venous thrombosis.
Table 2 Contraindications for using cardiac medications
Condition Contraindicated drug Number of patients
Active bleeding Antiplatelets 2
Bradycardia
(heart rate ≤ 55 bpm)
β-blockers 6
Hyperkalemia ACEIs/ARBs 1
Acute renal injury ACEIs/ARBs 3
CPK: creatine phosphokinase.
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considered consistent with the guidelines if it was pre-
scribed; and also if it was not prescribed when a contra-
indication, intolerance, or patient refusal was documented.
Secondary endpoints included whether patients received
counseling about their disease state, medications, and life-
style modification.
Continuous variables are expressed as mean ± SD, and
categorical variables are presented as frequencies and
percentages.
Results
The study included 186 patients. The baseline character-
istics of the study patients are shown in Table 1. The
mean age of patients was 63 ± 11.79 years, 70.4% being
men. Fifty three (28.5%) of the study patients were diag-
nosed with STEMI, 64 (34.4%) NSTEMI, and 69 (37.1%)
USA. Sixty two patients (33.3%) were treated medically
while 124 (66.7%) underwent percutaneous coronary
intervention (PCI).
Some patients had contraindications for receiving certain
medications, including bleeding, bradycardia, and hyperka-
lemia (Table 2). After accounting for contraindications or
intolerance, 62.9% of patients were discharged on a com-
bination of dual antiplatelet agents, a β-blocker, an ACEI or
ARB, and a statin as recommended by ACC/AHA guideline
(Kushner et al. 2009; Anderson et al. 2013). Among eligible
patients, 98.9% were appropriately discharged on aspirin,
89.1% on dual antiplatelet therapy (aspirin plus a theinopyr-
idine or ticagrelor), 90.5% on a β-blocker, 81.9% on an
ACEI or ARB, and 89.8% on a statin (Table 3).
Clopidogrel, ramipril, atorvastatin and bisoprolol were
the most commonly prescribed antiplatelet (other than as-
pirin), ACEI, statin, and β-blocker agents at a rate of 95.7%,
56.4%, 50.9% and 86.4%, respectively. Statins were pre-
scribed at different doses with the moderate and the highest
dose being the most commonly prescribed (Table 4).
55.1% of the patients were counseled about their dis-
ease and drug therapy, 92.2% of smokers about smoking
cessation, and 55.9% about life style changes including
diet modification and exercise.
Discussion
The combination of dual antiplatelet agents, a β-
blocker, an ACEI or ARB, and a statin is recommended
by ACC/AHA guideline for most patients with ACS,
unless contraindicated. Our study evaluated the appro-
priate prescription of cardiac medications upon hospital
discharge in patients admitted for ACS and showed that
only 62.9% of eligible patients were discharged on the
guideline-recommended medications. The prescription
rate for aspirin was 98.9%, for dual antiplatelet therapy
89.1%, for β-blockers 90.5%, for ACEIs or ARBs 81.9%,
for statins 89.8% and for nitroglycerin 19.35%.Numerous studies from different countries have re-
ported underuse of optimal medical therapies at hospital
discharge. Lee et al. reported in their study done in Korea
that the discharge prescription rates of all 4 medications
(antiplatelet drugs, β-blockers, ACEIs/ARBs, and statins)
Table 3 Proportion* of patients discharged on cardiac medications
Drug Aspirin Thienopyridines or ticagrelor β-blockers ACEIs or ARBs Statins Nitrates
Proportion 182/184 164/184 162/179 149/182 167/186 36/186
Percentage (98.9%) (89.1%) (90.5%) (81.9%) (89.8%) (19.4%)
*Proportions describe number of patients discharged on a certain medication divided by the number of patients with no contraindication (eligible) for
that medication.
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centage to be 57% in Australia (Wai et al. 2012). The pre-
scription rate was 48% in China as reported by Bi et al. (Bi
et al. 2009). In addition, Al-Zakwani et al. reported in their
study done in 6 Middle Eastern countries that 49% of the
patients received the quadruple medications at discharge
(Al-Zakwani et al. 2011). In France, a study of nationwide
registry found that the percentage was only 27% (Danchin
et al. 2005). In our study, 62.9% of patients were receiving
concomitantly all 4 medications, a percentage that is higher
than that described in other countries yet lower than ideal.
The higher percentage of prescribing of cardiac medica-
tions could be attributed to the fact that we conducted the
study in 2 teaching hospitals where compliance with guide-
lines is expected to be high. Nevertheless, physicians in the
2 hospitals are suboptimally prescribing the cardiac medica-
tions as per ACC/AHA guidelines.
The use of each cardiac medication upon hospital dis-
charge in ACS patients varies from one study or country to
another. Austin et al. evaluated the use of cardiac medica-
tions at hospital discharge for patients with MI in Canada.
Overall, 35.6% of patients received an statin, 58.2% ACEIs
and 71.0% β-blockers (Austin et al. 2006). Lee et al. re-
ported in their study done in Korea that the discharge pre-
scription rates of antiplatelet drugs, β-blockers, ACEIs/
ARBs, and statins were 99.0%, 72.7%, 81.5%, and 77.2%, re-
spectively (Lee et al. 2010). In Australia, Wachtel et al.
found that the prescribing rates for ACS medications were:
aspirin 90%, β-blockers 55%, ACEIs or ARBs 42%, lipid
lowering medication 66% and clopidogrel 64% (Wachtel
et al. 2008). Moreover, among ACS patients in Australia,
Wai et al. reported that at discharge, 97% received anti-
platelet agents, 75% β-blockers, and 78% ACEIs or ARBs
(Wai et al. 2012). Furthermore, in Spain, de Velasco et al.
reported that at discharge, 94.1% of MI patients received
antiplatelet drugs, 59.4% β-blockers, 51.2% ACEIs or ARBs,
and 87% received statin therapy (de Velasco et al. 2004). Fi-
nally, in New Zealand, Tang et al. reported that upon dis-
charge, the use of aspirin was 98%, β-blockers 80%, ACEIs
or ARBs 55%, and statins 70% (Tang et al. 2005). Again, in
our study, the percentage of patients discharged on each ofTable 4 Pattern of statin dosing upon discharge
High dose statin Moderate dose statin Low dose statin
37.7% 37.7% 24.6%
High dose statin: maximal recommended dose of a given statin.
Low dose statin: starting dose of a given statin.the 4 cardiac medications was higher than that described
in the above mentioned studies.
In our study, the rate of aspirin prescription is high
(98.9%) and comparable, or higher than previous studies
and this might be related to the different indications of as-
pirin in diseases other than ACS. 38.2% of our patients had
diabetes mellitus, 5.4% had a history of ischemic stroke and
5.91% had atrial fibrillation which support its high use in
these diseases (Association 2011; Samuel Wann et al.
2011). Two patients didn’t receive antiplatelet therapy upon
discharge because they had active bleeding during hospital
stay which is a major contraindication for its use (Kushner
et al. 2009; Anderson et al. 2013). Of the eligible patients,
9.8% received aspirin only and not dual antiplatelet therapy
and warfarin or dabigatran were used, along with aspirin, in
4 patients with atrial fibrillation. Some physicians fear the
use of triple antithrombotic therapy although studies re-
ported the beneficial combination of the 3 drugs when the
anticoagulant has an indication. In a meta-analysis on the
use of triple antithrombotic therapy in ACS patients, Gao
et al. reported that the triple therapy had significant reduc-
tion in ischemic stroke (P = 0.0004) as compared with dual
antiplatelet therapy but is associated with more bleeding
(Gao et al. 2011).
The majority of patients were discharged on clopidogrel
(95.7%) while only 6 were discharged on prasugrel (3.7%)
and one on ticagrelor (0.6%). This can be explained by the
lower cost of clopidogrel and the relatively recent approval
of prasugrel and ticagrelor at the time our study was con-
ducted (Jneid et al. 2012).
The rate of prescriptions of β-blockers in our study was
90.5%. Six patients did not receive this therapy due to re-
ported bradycardia (<55 bpm). However, 17 patients didn’t
have any contraindication for this therapy and were not
discharged on β-blockers. 3.2% of patients were discharged
on a calcium channel blocker (CCB) instead of a β-blocker
and they were already on a CCB at home. Keeping those
patients on CCBs is not justified as it is reasonable to give
CCB to patients in whom β-blockers are contraindicated
(i.e. bronchospastic disease) for relief of ischemia but not
as first line therapy (Kushner et al. 2009; Anderson et al.
2013).
Moreover, 10 patients with chronic obstructive pulmon-
ary disease (COPD) were discharged on β1 selective
blockers. Chen et al. reported that the use of β-blockers in
patients with ACS and COPD was significantly associated
with decreased one-year mortality (p < 0.02) given that
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2001). To note, in our study patients’ COPD symptoms
were well controlled and did not worsen with the use of
the selective β-blockers.
As compared to other cardiac medications, there was a
trend towards lower prescribing rates for ACEIs or ARBs
in our study. 81.9% of patients were discharged on ACEIs
or ARBs with ramipril being the most commonly pre-
scribed ACEI (56.4%). To note, ramipril, enalapril, capto-
pril and trandolapril are the most studied ACEIs and show
comparable efficacy (Frishman and Cheng 1999). TRACE,
AIRE, SOLVD and SAVE trials investigate the effect of dif-
ferent ACEIs in ACS patients and they showed reduction
in mortality and recurrence of MI (Frishman and Cheng
1999; Kober et al. 1995; AIRE study investigators 1993). A
possible explanation to the high use of ramipril is being
the formulary ACEI in both hospitals.
In our study, 89.8% of patients were discharged on sta-
tins with atorvastatin being the most commonly pre-
scribed (88 out of 167 prescriptions (52.7%)). Despite the
relatively high prescription rate of statins in our study,
they were not prescribed at the high doses that were
proven to offer more protection against major cardiovas-
cular events in clinical trials as compared to lower doses.
High dose statin was only prescribed for 37.7% of patients.
PROVEIT TIMI-22 and IDEAL trials investigate the role
of intensive therapy with pravastatin, atorvastatin and sim-
vastatin as compared to moderate therapy and they show
that high doses significantly reduce first occurrence of
death, MI, stroke, angina requiring re-hospitalization, or
revascularization after ACS event (Murphy et al. 2009;
Pedersen et al. 2005).
As for short acting nitrates, only 19.4% of ACS patients
were discharged on nitroglycerin. Short acting nitrates are
used on as needed basis and are usually not needed after
patients undergo successful PCI whereby atherosclerotic
coronary arteries get fixed.
Despite some advances in prescribing cardiac drugs
upon discharge as per guideline, Eagle et al. reported that
discontinuation of therapy was observed at 6-month
follow-up in 8% of patients taking aspirin on discharge,
12% of those taking beta-blockers, 20% of those taking
ACEIs, and 13% of those taking statins (Eagle et al. 2004).
Reasons of non-adherence may be attributed to poor com-
munication and education about the importance of ther-
apy at the time of hospital discharge (Kripalani et al.
2007). In our study, only 55.1% of patients were counseled
on their drug therapy which may increase the risk of non-
compliance. Hospitals should have a focus discharge coun-
seling on informing patients of major diagnoses, medica-
tion changes, dates of follow-up appointments, and
provide detailed discussion on the importance, indication
and adverse effects of each drug so that patients will ad-
here to therapy (Albert 2008). In addition, only 55.9% wereeducated about life style changes and 92.2% of smokers
about smoking cessation. Available studies show convin-
cingly the health benefits of lifestyle changes in CAD pa-
tients (Iestra et al. 2005).
There are several limitations of our study. First, it was
an observational study and done during a relatively short
period of time. Second, although we accounted for medi-
cation contraindication when assessing guideline adher-
ence, undocumented medication contraindications might
have existed. Consequently, we may have underestimated
the prescription rates for the drugs studied.
Conclusion
Hospital discharge offers a major opportunity for quality
improvement interventions since it is the linkage point be-
tween in-patient and out-patient care. This study provides
insights on the pattern of discharge prescriptions of ACS
patients in 2 Lebanese hospitals. Despite the beneficial out-
comes of cardiac medications, the rate of prescription re-
mains suboptimal and varies among classes where aspirin
remains on top of the list followed by β-blockers, statins,
and ACEIs or ARBs. Clinicians should provide medical
counseling to all ACS patients about their disease and its
progression and demand pharmacy counseling for all car-
diac medications to ensure patients’ better understanding
of the drug indication and importance.
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